chartexchange

CARA
Cara Therapeutics, Inc.
stockNASDAQ

InactiveApr 15, 2025
15.96USD-4.142%(-0.69)79,048
Loading…
Loading…
Sector
Healthcare
Industry
Biotechnology
CEO
Derek Chalmers
HQ
Stamford, Connecticut, USA
Apr 16, 2025 · 1-for-3 (reverse)
CARA Profile

cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

CARA Performance
PeriodPriceDateChange